FEBS Journal,
Journal Year:
2018,
Volume and Issue:
285(16), P. 2926 - 2943
Published: June 12, 2018
Solute
carriers
of
the
glucose
transporter
(
GLUT
)
family
mediate
first
step
for
cellular
usage.
The
upregulation
s
has
been
reported
in
numerous
cancer
types
as
a
result
perturbation
gene
expression
or
protein
relocalization
stabilization.
Because
they
enable
to
sustain
energy
demand
required
by
tumor
cells
various
biochemical
programs,
are
promising
targets
development
anticancer
strategies.
Recently,
important
biological
insights
have
come
from
fine
crystal
structure
determination
several
s;
these
advances
will
likely
catalyze
new
selective
inhibitory
compounds.
Furthermore,
deregulated
metabolism
nontumor
mass
is
beginning
be
appreciated
and
could
major
implications
our
understanding
how
uptake
specific
cell
influences
behavior
neighboring
same
microenvironment.
In
this
review,
we
discuss
some
deregulation
mechanisms
transporters,
their
genetic
pharmacological
targeting
cancer,
functions
may
environment
beyond
glycolysis.
Frontiers in Oncology,
Journal Year:
2019,
Volume and Issue:
9
Published: Nov. 1, 2019
Tumor
cells
must
generate
sufficient
ATP
and
biosynthetic
precursors
in
order
to
maintain
cell
proliferation
requirements.
Otto
Warburg
showed
that
tumor
uptake
high
amounts
of
glucose
producing
large
volumes
lactate
even
the
presence
oxygen,
this
process
is
known
as
"Warburg
effect
or
aerobic
glycolysis".
As
a
consequence
such
there
an
acidification
extracellular
pH
microenvironment,
ranging
between
6.0-6.5.
This
acidosis
favors
processes
metastasis,
angiogenesis
more
importantly,
immunosuppression,
which
has
been
associated
worse
clinical
prognosis.
Thus,
should
be
thought
important
oncometabolite
metabolic
reprogramming
cancer.
In
review,
we
summarized
role
regulating
microenvironment
cancer
discuss
its
relevance
up-regulation
enzymes
dehydrogenase
(LDH)
monocarboxilate
transporters
(MCTs)
tumors.
The
goal
review
expose
not
only
secondary
product
cellular
waste
cells,
but
also
key
molecule
involved
carcinogenesis
well
immune
evasion.
Finally,
possible
targeting
production
treatment
discussed.
